Clinical trials: Basal Cell Cancer
Basal Cell Carcinoma, Squamous Cell Carcinoma
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
Midazolam is an approved sedative medication used for medical procedures. This study was being done to document the safety and efficacy of midazolam in improving anxiety, heart rate, and blood pressure in patients prior to…
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
- Trial name
- NCT00578214
- Testing
- Randomized Midazolam, Local Anesthesia, Prospective Midazolam
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Basal Cell Carcinoma, Squamous Cell Carcinoma
Electronic Brachytherapy for the Treatment of NMSC
The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System.
- Trial name
- NCT01016899
- Testing
- electronic brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 187 people
- Sponsor
- Xoft, Inc.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Non-melanomatous Skin Cancer
Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acitretin may stop cancer from growing in patients at high risk for basal cell carcinoma or squamous cell carcinoma of the skin.
- Trial name
- NCT00644384
- Testing
- acitretin, gene expression analysis, northern blotting
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
BCC, BCC - Basal Cell Carcinoma
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell…
- Conditions
- BCC, BCC - Basal Cell Carcinoma, Basal Cell Carcinoma, Basal Cell Cancer
- Trial name
- NCT04552990
- Testing
- Jet injection of ALA, Surgical excision, Illumination
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris
The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other…
- Conditions
- Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
- Trial name
- NCT00005660
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA II - PET Imaging Optimization
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04706910
- Testing
- 18F-DOPA, Furosemide Injection
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University of Alberta
Basal Cell Carcinoma
Clinical Diagnosis of Basal Cell Carcinoma Subtype
Skin cancer is the most common cancer in Caucasians. Basal cell carcinoma (BCC) is the most frequent skin cancer with around 44.000 new tumours per year in the Netherlands, and its incidence is still rising.
- Trial name
- NCT01370824
- Testing
- Punch biopsy, Surgical excision
- Where
- 2 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Basal Cell Carcinoma, Squamous Cell Carcinoma
HRQoL Keratinocyte Carcinomas
Rationale: Keratinocyte skin cancer is known to influence the HRQoL in a specific way. Derived utility values are required for cost-effectiveness analyses of new interventions.
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Actinic Keratoses
- Trial name
- NCT04814953
- Testing
- questionnaires
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 2,400 people
- Sponsor
- University Hospital, Ghent
Carcinoma, Basal Cell
Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas
Basal cell carcinoma (BCC) is the most frequent skin cancer. Uncontrolled growth destroys local anatomic structures. There are various treatment alternatives with different recurrence rates and expenses.
- Trial name
- NCT00515970
- Testing
- Curettage, Deep excision, Shave excision
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- University Hospital Tuebingen
Basal Cell Carcinoma
Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study
25 patients with primary low-risk basal cell carcinoma treated with calcium electroporation
- Trial name
- NCT05046262
- Testing
- Calcium chloride
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Bispebjerg Hospital
Carcinoma, Basal Cell
HIFU for Treatment of Non-nodular and Recurrent BCC
The overall objective of this study is to demonstrate the safety and efficacy of removal of Basal Cell Carcinoma (BCC) using a new investigational equipment based on high-intensity focused ultrasound.
- Trial name
- BCC-HIFU2101 (NCT05133427)
- Testing
- TOOsonix system ONE-M
- Where
- 2 sites in Denmark
- Volunteers
- 28 people
- Sponsor
- Joergen Serup
Basal Cell Carcinoma
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome.
- Trial name
- NCT01604252
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 503 people
- Sponsor
- Genentech, Inc.
Skin Cancer
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center.
- Trial name
- NCT07177638
- Testing
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Basal Cell Carcinoma, Gorlin Syndrome
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
This was a phase II, double-blind, randomized, proof-of-concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with NBCCS.
- Conditions
- Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome
- Trial name
- NCT01350115
- Testing
- LDE225
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Nodular Basal Cell Carcinoma of Skin
Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma
Evaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy.
- Trial name
- NCT07381972
- Testing
- Control Arm (Conventional Therapy), Experimental arm
- Where
- Brazil
- Volunteers
- 142 people
- Sponsor
- University of Sao Paulo
Basal Cell Carcinoma
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic…
- Trial name
- NCT04928222
- Testing
- Doxorubicin-containing MNA
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- SkinJect, Inc.